Financial Wire

New Found Gold Up In US Premarket As Announces $205M Funding Package to Advance Queensway Project

-- New Found Gold (NFG.V) was at last look up 1.6% in US Premarket trade Monday after announcing a $205 million finance package made up of a $100 million bought deal shares financing with lead orders from EdgePoint Investment Group and cornerstone investor Eric Sprott and a $105 million senior secured credit facility with EdgePoint.

In a statement it said proceeds will be used to advance the Queensway gold project in Newfoundland.

The company will issue 33.8 million shares at $2.96 each, to raise $100 million. The underwriters have also been granted a 15% over-allotment option.

New Found Gold has also sealed a deal with EdgePoint for a secured credit facility of up to $105 million. The funds will be advanced in two tranches: $70 million and $35 million. Both tranches will be released when certain conditions are met.

In return, New Found Gold will issue non-transferable share purchase warrants to EdgePoint totalling US$9 million: US$6 million worth of warrants will be issued on Tranche 1, which will be exercisable for 2.5 million shares at $3.30 each. The Tranche 2 warrants, totalling US$3 million will be exercisable for shares at a price equal to a 25% premium to the closing price of the shares on the TSX Venture immediately before the Tranche 2 funding date.

New Found Gold says the $205 million funding package covers the initial capital expenditures required to bring its flagship Queensway Gold Project-Phase I into production. It added that it will not proceed with the US$75 million secured loan facility and warrants issue with Nebari Natural Resources Credit Fund II, announced in early March.

New Found Gold closed up $0.09 or 3.1% to $2.96, on the TSX Venture Exchange on Friday.

Related Articles

Australia

Arcus Biosciences Discontinues Phase 3 Lung Cancer Trial for Futility

Arcus Biosciences (RCUS) said Monday it discontinued its phase 3 STAR-121 study in metastatic non-small cell lung cancer after an Independent Data Monitoring Committee recommended stopping the trial for futility.The study, conducted in collaboration with Gilead Sciences (GILD), evaluated domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment, the company said.The decision followed a pre-planned futility analysis indicating the treatment was unlikely to meet its primary endpoint.Shares of Arcus Biosciences were down 5% in Monday trading.Price: $23.05, Change: $-1.20, Percent Change: -4.95%

$GILD$RCUS
Australia

Sila Realty Trust to be Taken Private by Blue Owl Affiliates in $2.4 Billion Deal

Sila Realty Trust (SILA) agreed to be acquired and taken private by certain affiliates of Blue Owl Capital's (OWL) real estate unit in an all-cash deal worth roughly $2.4 billion.Shareholders of net lease real estate investment trust Sila will receive $30.38 per share, representing a 19% premium to the stock's closing price on Friday, the companies said Monday.The transaction, which requires approval from Sila's shareholders, is anticipated to complete in the second or third quarter of this year. Upon completion, the company will be delisted from the New York Stock Exchange."The consummation of this transaction will provide significant and immediate realized benefit to our shareholders," Sila Chief Executive Michael Seton said in a statement.Shares of Sila were up 19% in Monday trade. Asset manager Blue Owl rose 1%.Sila, which is focused on investing in healthcare facilities, said its portfolio comprised 137 real estate properties and three undeveloped land parcels in the US as of end-March. Data on its website showed its portfolio includes 86 medical outpatient buildings, 25 inpatient rehabilitation facilities, and 26 surgical and specialty facilities."This transaction provides us with a compelling opportunity to acquire a scaled portfolio with durable cash flows and attractive long-term growth characteristics, while further expanding Blue Owl managed funds' exposure to an asset class and sector we view as both resilient and essential given its critical role in both society and the economy," Marc Zahr, co-president and global head of real assets at Blue Owl, said.In February, Sila reported fourth-quarter adjusted funds from operations of $0.55 per share, up from $0.54 a year ago. Revenue rose to $50.7 million from $46.5 million.Sila plans to pay up to two regular quarterly dividends ahead of deal completion.Price: $30.44, Change: $+4.90, Percent Change: +19.19%

$OWL$SILA
Australia

Carnival Shareholders Approve Single Company Structure, Redomiciliation

Carnival (CCL, CUK) said Monday that majority of its shareholders approved the proposal to simplify its dual-listed structure into a single company and the redomiciliation of Carnival Corporation to Bermuda from Panama.The company said it expects the proposed changes to become effective on May 7.Price: $28.69, Change: $-0.53, Percent Change: -1.81%

$CCL$CUK